Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute bioavailability and pharmacokinetics study of BAY 2433334 in healthy male volunteers
NL-OMON49790Active, not recruiting
- Sponsor
- Bayer
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of asundexian in thromboembolism and coronary arteriosclerosis, sponsored by Bayer. Primary endpoints: Absolute bioavailability of BAY 2433334 and Pharmacokinetics of BAY 2433334. Started Jul 2020; status: active, not recruiting.
02
Drugs
asundexian
03
Conditions
thromboembolismcoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON49790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49790.